$167 Million is the total value of Stonepine Capital Management, LLC's 27 reported holdings in Q4 2017. The portfolio turnover from Q3 2017 to Q4 2017 was 61.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ENTA | Sell | ENANTA PHARMACEUTICALS INC | $12,818,000 | -29.8% | 218,434 | -44.0% | 7.68% | -28.6% |
| BDSI | Sell | BIODELIVERY SCIENCES INTL | $10,754,000 | -5.7% | 3,645,491 | -5.7% | 6.44% | -4.2% |
| REPH | Sell | RECRO PHARMA INC | $9,714,000 | -25.7% | 1,050,115 | -27.9% | 5.82% | -24.4% |
| OPHT | Sell | OPHTHOTECH CORP | $7,332,000 | -25.4% | 2,350,000 | -32.6% | 4.39% | -24.2% |
| NVLNF | Sell | NOVELION THERAPEUTICS INC | $5,288,000 | -58.8% | 1,694,717 | -7.2% | 3.17% | -58.1% |
| CBMX | Exit | COMBIMATRIX CORP | $0 | – | -63,283 | -100.0% | -0.28% | – |
| TRIB | Exit | TRINITY BIOTECH PLCspon adr new | $0 | – | -122,668 | -100.0% | -0.41% | – |
| CASM | Exit | CAS MEDICAL SYSTEMS INC | $0 | – | -812,718 | -100.0% | -0.44% | – |
| ICPT | Exit | INTERCEPT PHARMACEUTICALS IN | $0 | – | -18,600 | -100.0% | -0.64% | – |
| OXFD | Exit | OXFORD IMMUNOTEC GLOBAL PLC | $0 | – | -162,286 | -100.0% | -1.61% | – |
| VCEL | Exit | VERICEL CORP | $0 | – | -975,711 | -100.0% | -3.45% | – |
| AVDL | Exit | AVADEL PHARMACEUTICALS PLCsponsored adr | $0 | – | -985,210 | -100.0% | -6.10% | – |
| PCRX | Exit | PACIRA PHARMACEUTICALS INC | $0 | – | -375,200 | -100.0% | -8.30% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-02-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CTI Biopharmap Corp. | 24 | Q1 2023 | 14.8% |
| APOLLO ENDOSURGERY INC | 23 | Q1 2023 | 15.6% |
| XOMA CORP | 20 | Q3 2023 | 5.7% |
| Cumberland Pharmaceuticals, Inc. | 19 | Q4 2020 | 7.0% |
| Amarin Corp PLC - SPONS ADR | 14 | Q3 2022 | 23.2% |
| VANDA PHARMACEUTICALS INC | 14 | Q3 2023 | 20.9% |
| BIODELIVERY SCIENCES INTL | 14 | Q1 2020 | 12.9% |
| AFFIMED NV | 13 | Q3 2022 | 7.7% |
| ALIMERA SCIENCES INC | 13 | Q3 2019 | 4.2% |
| VIVEVE MEDICAL INC | 12 | Q2 2019 | 15.3% |
View Stonepine Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CTI BIOPHARMA CORP | April 13, 2023 | 7,018,046 | 5.3% |
| ADMA BIOLOGICS, INC. | February 13, 2023 | 6,940,000 | 3.1% |
| Amryt Pharma plc | February 13, 2023 | 31,666,195 | 9.9% |
| Apollo Endosurgery, Inc. | February 13, 2023 | 4,351,088 | 9.0% |
| Conformis Inc | February 13, 2023 | 748,194 | 9.9% |
| Ovid Therapeutics Inc.Sold out | February 13, 2023 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | February 14, 2022 | 0 | 0.0% |
| CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Conformis Inc | February 14, 2022 | 14,768,823 | 7.9% |
| YUMANITY THERAPEUTICS, INC.Sold out | February 14, 2022 | 0 | 0.0% |
View Stonepine Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-04-19 |
| 13F-HR | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
View Stonepine Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.